The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 8, 2005, Pages 572-578

  Siegman Igra, Yardena ^a,b   Reich, Prachia ^a   Orni Wasserlauf, Ruth ^a,b   Schwartz, David ^b   Giladi, Michael ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; COTRIMOXAZOLE; FUSIDIC ACID; METICILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PENICILLIN ALLERGY; PERSISTENT INFECTION; RECURRENT INFECTION; RELAPSE; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; SUPERINFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOXACILLIN; FEMALE; HUMANS; ISRAEL; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 24644489678     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540510038488     Document Type: Article

References (19)

1. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N. Treatment and outcome of Staphylococcus aureus bacteraemia. A prospective study of 278 cases. Arch Intern Med 2002;162:25-32.
2. Kim SH, Park WB, Lee KD, Kang CI, Kim HB, Oh MD, et al. Outcome of Staphylococcus aureus bacteraemia in patients with eradicable versus non-eradicable foci. Clin Infect Dis 2003;37:794-9.
3. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteraemia. Clin Infect Dis 2003;36:1418-23.
4. Johnson LB, Almoujahed MO, Ilg K, Maolood L, Khatib R. Staphylococcus aureus bacteraemia: compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003;35:782-9.
5. Fowler VG Jr, Kong LK, Corey GR, Gottlieb GS, McClelland RS, Sexton DJ, et al. Recurrent Staphylococcus aureus bacteraemia: pulse-field gel electrophoresis findings in 29 patients. J Infect Dis 1999;179:1157-61.
6. Fowler VG Jr, Sanders LL, Kong LK, McClelland RS, Gottlieb GS, Li J, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999;28:106-14.
7. Chang FY, Peacock JE, Musher DM, Triplett P, MacDonald BB, Mylotte JM, et al. Staphylococcus aureus bacteraemia recurrence and the impact of antibiotic treatment in a prospective multicentre study. Medicine 2003;82:333-9.
8. Fowler VG Jr, Olsen MK, Correy R, Woods CW, Cabell CH, Reller LB, et al. Clinical identifiers of complicated Staphylococcus aureus bacteraemia. Arch Intern Med 2003;163: 2066-72.
9. Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, et al. A prospective multicentre study of Staphylococcus aureus bacteraemia. Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine 2003;82:322-32.
10. Siegman-Igra, Y, Fourer B, Orni-Wasserlauf R, Golan Y, Noy A, Schwarz D, Giladi M. Reappraisal of community-acquired bacteraemia: a proposal of new classification for the spectrum of acquisition of bacteraemia. Clin Infect Dis 2002;34:1431-9.
11. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modification of the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30: 633-8.
12. Craven DE, Kolisch NR, Hsieh CR, Connolly MG Jr, McCabe WR. Vancomycin treatment of bacteraemia caused by oxacillin-resistant Staphylococcus aureus: comparison with beta-lactam antibiotic treatment of bacteraemia caused by oxacillin-sensitive Staphylococcus aureus. J Infect Dis 1983;147:137-43.
13. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990;34:1227-31.
14. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:739-41.
15. Eng RHK, Bishburg E, Smith SM, Scadutto P. Staphylococcus aureus bacteraemia during therapy. J Infect Dis 1987; 155:1331-4.
16. Cosgrove SE, Sakuolas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteraemia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
17. Peacock SJ, Curtis N, Berendt AR, Bowler ICJW, Winearls CG, Maxwell P. Outcome following haemodialysis catheter-related Staphylococcus aureus bacteraemia. J Hosp Infect 1999;41:223-8.
18. Gelfand MS, Cleveland KO. Vancomycin therapy and the progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis. South Med J 2004;97:593-7.
19. Daroviche RO. Treatment of infections associated with surgical implants. N Eng J Med 2004;350:1422-9.